The Patent Finder

Angiolab, Inc.

Also on record
Records under this name other than the patents Angiolab, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Showing 1 to 10 of 10 · Back to Angiolab, Inc.

PatentTitleStatus Expires Confidence
US 11,224,629Fraction of Melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same
Lapsed on the fee record
Ended Jan 18, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jan 18, 2026From the USPTO record
US 10,933,030Use of paeonol for inhibiting angiogenesis or for enhancing radiosensitization
Lapsed on the fee record
Ended Mar 2, 2025 · From the USPTO record
Lapsed on the fee recordEnded Mar 2, 2025From the USPTO record
US 10,894,071Fraction of melissa leaf extract having angiogenesis and MMP inhibitory activities, and composition comprising the same
Lapsed on the fee record
Ended Jan 19, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jan 19, 2025From the USPTO record
US 7,485,327Composition comprising Melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
Term ended
Term ended May 15, 2024 · From the USPTO record
Term endedTerm ended May 15, 2024From the USPTO record
US 7,163,805Human serum albumin-TIMP2 fusion protein, a polynucleotide encoding the same and a method of producing the human serum albumin-TIMP2 fusion protein
Term ended
Term ended Jan 18, 2024 · From the USPTO record
Term endedTerm ended Jan 18, 2024From the USPTO record
US 9,155,773Antiobesity composition
Term ended
Term ended Jun 27, 2022 · From the USPTO record
Term endedTerm ended Jun 27, 2022From the USPTO record
US 9,962,331Composition containing horse chestnut extract
Lapsed on the fee record
Ended May 8, 2022 · From the USPTO record
Lapsed on the fee recordEnded May 8, 2022From the USPTO record
US 7,572,831Composition containing chalcone
Lapsed on the fee record
Ended Aug 11, 2021 · From the USPTO record
Lapsed on the fee recordEnded Aug 11, 2021From the USPTO record
US 7,482,027Composition for the prevention or treatment of diseases associated with angiogenesis
Lapsed on the fee record
Ended Jan 27, 2021 · From the USPTO record
Lapsed on the fee recordEnded Jan 27, 2021From the USPTO record
US 7,413,735Pharmaceutical composition comprising arginine deiminase for inhibiting angiogenesis
Lapsed on the fee record
Ended Aug 19, 2016 · From the USPTO record
Lapsed on the fee recordEnded Aug 19, 2016From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited